Azatyrosinamides: novel RAS-related anticancer agents

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Previous synthesis of novel azatyrosinamide derivatives selective for ras-transformed NIH3T3 cells with improved toxicity.
• Azatyrosine derivatives showed promise but required further investigation into their mechanism and efficacy.

Purpose of the Study:

• To investigate the mechanism of action of novel azatyrosinamide derivatives.
• To evaluate the antitumour activity of these compounds in ras-transformed cells both in vitro and in vivo.

Main Methods:

• Screening of nine azatyrosinamides for anticancer activity in wild-type and ras-transformed NIH3T3 cells.
• In vitro and in vivo testing of the most active compounds (HPW98-1 and HPW98-2).
• Assays included apoptosis induction, anchorage-independent growth inhibition, and xenograft tumor growth attenuation.

Main Results:

• HPW98-1 and HPW98-2 induced apoptosis and inhibited anchorage-independent growth in ras-transformed NIH3T3 cells.
• Excess tyrosine counteracted azatyrosine's effect but not that of HPW98-1 and HPW98-2, suggesting a different mechanism.
• HPW98-1 inhibited angiogenesis and reduced tumor growth in ras-transformed NIH3T3 and SW620 xenografts.

Conclusions:

• The novel azatyrosinamide HPW98-1 exhibits significant antitumour activity.
• HPW98-1's efficacy in inhibiting tumor growth and angiogenesis warrants further investigation.
• HPW98-1 shows potential for the treatment of RAS-related cancers.